ESMYA (Ulipristal 5mg tablets)
Posted in News
The marketing authorisation for Esmya (Ulipristal 5mg tablets) was suspended on 20th March 2020 following reports of a further case of liver injury necessitating liver transplant. The manufacturer recalled all stock from patients, pharmacies and wholesalers. This formulation of ulipristal had been licensed for treatment of uterine fibroids in patients ineligible for surgery or pre-surgery.
The post-coital contraceptive EllaOne (ulipristal 30mg tablets) has not been associated with liver injury and remains available.